A pre-grant opposition has been filed against the anti-HIV drug, Combivir, manufactured by GlaxoSmithKline, a leading pharmaceutical company . The Manipur Network of Positive People (MNP+) and the Indian Network of People Living with HIV/AIDS have lodged the complaint at the Kolkata patent office.
The drug formulation is a combination of two essential anti-HIV drugs Lamivudine and Zidovudine and is not a new formulation, said a release. The grant of a patent is believed to make the anti-retroviral treatment expensive for patients afflicted with the deadly disease.
Advertisement'We are objecting to the patenting of Combivir because it is not a new invention but simply the combination of two existing drugs,' said K K Abraham, president, INP+.
A similar opposition was raised regarding patenting anti-cancer drug, Gleevac, manufactured by Novartis. The patent was turned down subsequently as it was found to nothing more than a new form of an old drug.
Combivir is one of the anti-retroviral drugs used by numerous AIDS/HIV organizations, worldwide. A fixed dose combination of the drug is used in several projects targeted at provision of cheap and effective AIDS/HIV treatment to those who cannot afford the same.
In India, more than 5.1 million people are afflicted with AIDS/HIV and a majority of these are solely dependent on the generic drugs provided by the national HIV/AIDS treatment program. The issue of a patent can lead to domination with respect to drug manufacture, thereby restricting the production of effective and affordable drug alternatives.
PHIV Patients Opposes Patenting Of AIDS Drug Ranbaxy Expands By Acquiring A Generic Company In Belgium M
You May Also Like